Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma (LDT-RFA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00728078
Recruitment Status : Unknown
Verified February 2009 by Sun Yat-sen University.
Recruitment status was:  Recruiting
First Posted : August 5, 2008
Last Update Posted : February 9, 2009
Information provided by:
Sun Yat-sen University